Trial record 19 of 28 for:    aplastic anemia | Open Studies | NIH, U.S. Fed

Diamond Blackfan Anemia Registry (DBAR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by North Shore Long Island Jewish Health System
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jeffrey Lipton, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT00106015
First received: March 18, 2005
Last updated: June 3, 2014
Last verified: June 2014
  Purpose

The purpose of this study is to maintain a comprehensive registry of patients with the rare inherited bone marrow failure syndrome Diamond Blackfan anemia (DBA).


Condition
Anemia
Blood Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diamond Blackfan Anemia Registry (DBAR)

Resource links provided by NLM:


Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Understanding the epidemiology and biology of Diamond Blackfan anemia [ Time Frame: yearly ] [ Designated as safety issue: No ]

Estimated Enrollment: 700
Study Start Date: September 2004
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Detailed Description:

BACKGROUND:

Diamond Blackfan anemia (DBA) is a heterogeneous genetic disorder characterized by pure red cell aplasia, congenital anomalies, a predisposition to pancytopenia and myelodysplasia as well as hematopoietic and non-hematopoietic cancer. Anemia usually presents in infancy or early childhood and greater than 40% of patients have at least one congenital anomaly. The actuarial cancer risk is, as of yet, undetermined. One DBA gene has been cloned and the existence of at least two other DBA genes has been inferred by linkage analysis. Penetrance and expressivity of DBA genes are highly variable. "Affected" individuals within the same family may vary dramatically as to the degree of anemia, response to corticosteroids, the presence of congenital anomalies and the development of cancer. Despite improvements in understanding of this disorder there are significant deficiencies in knowledge that inhibit the exploitation of this syndrome to increase both specific and general knowledge of mechanisms of hematopoietic failure, birth defects and cancer predisposition. Furthermore this disease will, in the near future, provide a valuable platform to study complex gene interactions. There are less than 1000 individuals in the United States and Canada estimated to have DBA, representing at least 11 genotypes. Thus, no single center follows sufficient numbers of well-characterized patients for meaningful clinical and laboratory investigations. Furthermore, clinicians require an accurate knowledge of the clinical and laboratory presentation, mode of inheritance, treatment response, outcomes and prognosis to make important diagnostic treatment and reproductive decisions. A comprehensive registry that captures this information and characterizes patients accurately is therefore essential to advance our understanding of DBA, and in the process, knowledge regarding hematopoietic cell differentiation, birth defects and cancer predisposition. The registry will be an essential component of clinical and laboratory DBA related research and patient care.

The Diamond Blackfan Anemia Registry (DBAR) was established in 1992, and families were asked to participate if a member was affected by the disorder. From this, the Diamond Blackfan Anemia Foundation (DBAF) was established, largely as a cooperating entity for families to share information. The registry attempts to establish contact with all affected individuals at the time of diagnosis, avoiding the pitfalls of reporting bias inherent to the study of many diseases for which extraordinary events prompt referral to specialized centers. The registry is already capturing a high percentage of the estimated number of new cases per year, and has facilitated genetic studies to define the gene(s) responsible for the disorder. Thus, the registry has an established track record based on funding from non-NIH sources.

The study is in response to RFA HL-04-008 on Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow Failure Syndromes.

DESIGN NARRATIVE:

The objective of this study is to expand and update the DBAR in order to: 1) facilitate investigations into the epidemiology and biology of Diamond Blackfan anemia; 2) provide an accurate phenotype of DBA patients to facilitate genotype- phenotype correlations; 3) provide access of well characterized patients to treatment protocols; 4) provide patients to access to research studies; 5) provide patients with results of research studies; 6) serve as a resource to patients and their doctors to guide diagnostic, therapeutic, and reproductive decisions.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All subjects diagnosed with Diamond Blackfan anemia

Criteria

Inclusion Criteria:

  • Patients must meet the diagnostic criteria for DBA which include the following:

    1. Normochromic, usually macrocytic and occasionally normocytic anemia developing early in childhood
    2. Reticulocytopenia
    3. Normocellular bone marrow with a selective deficiency of red cell precursors
    4. Normal or slightly decreased leukocyte count
    5. Normal or often increased platelet count
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00106015

Contacts
Contact: Eva Atsidaftos, MA 516-562-1504 eatsidaf@nshs.edu

Locations
United States, New York
Cohen Children's Medical Center of NY Recruiting
New Hyde Park, New York, United States, 11040
Contact: Eva Atsidaftos, MA    518-562-1504    eatsidaf@nshs.edu   
Principal Investigator: Jeffey M Lipton, MD, PhD         
Sub-Investigator: Adrianna Vlachos, MD         
Sponsors and Collaborators
North Shore Long Island Jewish Health System
Investigators
Principal Investigator: Jeffrey M Lipton, MD, PhD Cohen Children's Medical Center of NY /The Feinstein Institutute for Medical Research
Study Director: Adrianna Vlachos, MD Cohen Children;s Medical Center of NY/ The Feinstein Institute for Medical Research
  More Information

Additional Information:
Publications:

Responsible Party: Jeffrey Lipton, Director, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT00106015     History of Changes
Other Study ID Numbers: 1288, R01HL079571
Study First Received: March 18, 2005
Last Updated: June 3, 2014
Health Authority: United States: Federal Government

Keywords provided by North Shore Long Island Jewish Health System:
inherited pure red cell aplasia

Additional relevant MeSH terms:
Anemia
Hematologic Diseases
Anemia, Diamond-Blackfan
Anemia, Hypoplastic, Congenital
Anemia, Aplastic
Red-Cell Aplasia, Pure
Bone Marrow Diseases
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 22, 2014